Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2003-10-16
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00071188
- Locations
- ๐น๐ญ
Research Site, Chiang mai, Thailand
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00006257
- Locations
- ๐บ๐ธ
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
๐บ๐ธUniversity of California Davis Cancer Center, Sacramento, California, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 73
- Registration Number
- NCT00006012
- Locations
- ๐บ๐ธ
Galesburg Cottage Hospital, Galesburg, Illinois, United States
๐บ๐ธSiouxland Regional Cancer Center, Sioux City, Iowa, United States
๐บ๐ธSt. Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-08-07
- Target Recruit Count
- 800
- Registration Number
- NCT00070278
- Locations
- ๐ฌ๐ง
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3294
- Registration Number
- NCT00070564
- Locations
- ๐บ๐ธ
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
๐บ๐ธCancer Care Associates - Norman, Norman, Oklahoma, United States
๐บ๐ธRiverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 43
- Registration Number
- NCT00069953
- Locations
- ๐บ๐ธ
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
๐บ๐ธHubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-30
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT00003930
- Locations
- ๐บ๐ธ
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
๐บ๐ธIreland Cancer Center, Cleveland, Ohio, United States
๐บ๐ธHuntsville Hospital System, Huntsville, Alabama, United States
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 35
- Registration Number
- NCT00003449
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 84
- Registration Number
- NCT00003281
- Locations
- ๐บ๐ธ
CCOP - Ochsner, New Orleans, Louisiana, United States
๐บ๐ธCCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
๐บ๐ธCCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
- Conditions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00002559
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.